A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
David C. Wheeler(The George Institute for Global Health), Robert D. Toto(The University of Texas Southwestern Medical Center), Bergur V. Stefánsson(AstraZeneca (Sweden)), Niels Jongs(University of Groningen), Glenn M. Chertow(Stanford University), Tom Greene(University of Utah), Fan Fan Hou(Nanfang Hospital), John J.V. McMurray(University of Glasgow), Roberto Pecoits‐Filho(Pontifícia Universidade Católica do Paraná), Ricardo Correa‐Rotter(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Peter Rossing(Steno Diabetes Center), C. David Sjöström(AstraZeneca (Sweden)), Kausik Umanath(Wayne State University), Anna Maria Langkilde(AstraZeneca (Sweden)), Hiddo J.L. Heerspink(University of Groningen)
Cited by 392Open Access
Abstract
/year, respectively. Dapagliflozin reduced the urinary albumin-to-creatinine ratio by 26% relative to placebo. Adverse events leading to study drug discontinuation were similar with dapagliflozin and placebo. There were fewer serious adverse events with dapagliflozin, and no new safety findings in this population. Thus, in participants with IgA nephropathy, dapagliflozin reduced the risk of chronic kidney disease progression with a favorable safety profile.
Related Papers
No related papers found
Powered by citation graph analysis